Unaudited Financial Results for the quarter and half year ended 30-09-2025.
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals reported strong consolidated revenue of ₹22,253 lakhs in H1 FY26, up about 32% from ₹17,011 lakhs in H1 FY25, driven by robust sales of registered products across international markets. Q2 FY26 standalone revenue rose to ₹11,313 lakhs versus ₹9,003 lakhs in Q2 FY25 (about 25% growth). EBITDA grew 35% to ₹50 crore with margins expanding to 22.5% (from 22.0% in Q1 FY26), supported by better product mix and operational efficiency. Net profit after tax for H1 FY26 stood at ₹2,603.55 lakhs versus ₹1,680.19 lakhs (about 55% growth), with basic EPS of ₹25.09. The company generated positive operating cash flow of ₹2,676 lakhs, funded all capex through internal accruals, and aims to surpass its ₹500 crore revenue target for FY26.
Strong revenue and profit growth, expanding margins, and debt-free capex funded by internal accruals are positive signals for shareholders. The results reinforce management's growth trajectory and international expansion plans, likely to be viewed favorably by the market.